Antoun et al. reported that sorafenib‐treated mRCC patients (N = 80) progressively lost muscle mass during treatment and that the number of patients meeting the criteria for sarcopenia increased from 52.5% at sorafenib baseline to 71.0% after 1 year of treatment in a VEGFR‐TKI naïve population.10 The gene discussed is KDR; the disease is sarcopenia.